Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Hassel

Showing results (261-270 of 271) with videos related to

Pageof 28
Sort By:
Cell|August 21, 2020
IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor ProgressionAhmed Sadik, Luis F Somarribas Patterson, Selcen Öztürk, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2022
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)Jeffrey S Weber, Dirk Schadendorf, Michele Del Vecchio, et al.
European Journal of Cancer (Oxford, England : 1990)|September 5, 2025
Outcome of systemic therapy in patients with advanced rare skin cancers: A retrospective multicenter DeCOG study of 209 patientsSelma Ugurel, Nessr Abu Rached, Thilo Gambichler, et al.
European Journal of Cancer (Oxford, England : 1990)|March 18, 2021
Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibitionSarah Knispel, Maximilian Gassenmaier, Alexander M Menzies, et al.
Nature|July 31, 2020
An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanomaUgur Sahin, Petra Oehm, Evelyna Derhovanessian, et al.
Journal for Immunotherapy of Cancer|April 7, 2023
Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREGCindy Franklin, Peter Mohr, Leonie Bluhm, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2026
Hierarchical classification of immune cell transcriptomes at population-scaleChristopher Beltz, Zekai Qiu, Leon Sadowski, et al.
European Journal of Cancer (Oxford, England : 1990)|December 24, 2021
Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysisSimone M Goldinger, Kristina Buder-Bakhaya, Serigne N Lo, et al.
European Journal of Cancer (Oxford, England : 1990)|March 23, 2025
First-line checkpoint inhibitor therapy in metastatic acral lentiginous melanoma compared to other types of cutaneous melanoma: A multicenter study from the prospective skin cancer registry ADOREGSören Reinhard, Jochen Sven Utikal, Anne Zaremba, et al.
European Journal of Cancer (Oxford, England : 1990)|December 6, 2024
Improved survival of advanced melanoma patients receiving immunotherapy with concomitant antithrombotic therapy - A multicenter study on 2419 patients from the prospective skin cancer registry ADORegJulian Kött, Tim Zell, Noah Zimmermann, et al.
Pageof 28

Showing results (261-270 of 271) with videos related to

Sort By:
Pageof 28
Cell|August 21, 2020
IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor ProgressionAhmed Sadik, Luis F Somarribas Patterson, Selcen Öztürk, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2022
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)Jeffrey S Weber, Dirk Schadendorf, Michele Del Vecchio, et al.
European Journal of Cancer (Oxford, England : 1990)|September 5, 2025
Outcome of systemic therapy in patients with advanced rare skin cancers: A retrospective multicenter DeCOG study of 209 patientsSelma Ugurel, Nessr Abu Rached, Thilo Gambichler, et al.
European Journal of Cancer (Oxford, England : 1990)|March 18, 2021
Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibitionSarah Knispel, Maximilian Gassenmaier, Alexander M Menzies, et al.
Nature|July 31, 2020
An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanomaUgur Sahin, Petra Oehm, Evelyna Derhovanessian, et al.
Journal for Immunotherapy of Cancer|April 7, 2023
Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREGCindy Franklin, Peter Mohr, Leonie Bluhm, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2026
Hierarchical classification of immune cell transcriptomes at population-scaleChristopher Beltz, Zekai Qiu, Leon Sadowski, et al.
European Journal of Cancer (Oxford, England : 1990)|December 24, 2021
Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysisSimone M Goldinger, Kristina Buder-Bakhaya, Serigne N Lo, et al.
European Journal of Cancer (Oxford, England : 1990)|March 23, 2025
First-line checkpoint inhibitor therapy in metastatic acral lentiginous melanoma compared to other types of cutaneous melanoma: A multicenter study from the prospective skin cancer registry ADOREGSören Reinhard, Jochen Sven Utikal, Anne Zaremba, et al.
European Journal of Cancer (Oxford, England : 1990)|December 6, 2024
Improved survival of advanced melanoma patients receiving immunotherapy with concomitant antithrombotic therapy - A multicenter study on 2419 patients from the prospective skin cancer registry ADORegJulian Kött, Tim Zell, Noah Zimmermann, et al.
Pageof 28